NASDAQ · AUPH
Aurinia Pharmaceuticals Inc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AUPH: Nov 3, 2026
Aurinia Pharmaceuticals Inc Ordinary Shares is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $0.2. The reported EPS for the same quarter last year was $0.23.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.20 | $0.20 | $0.20 | 1 |
| Dec 2026 | $0.19 | $0.19 | $0.19 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · BNK Invest- RTTNews · Oct 30, 8:50 AM EDTAurinia Pharmaceuticals Inc. Q3 Sales Increase(RTTNews) – Aurinia Pharmaceuticals Inc. (AUP.V) revealed earnings for third quarter of $31.70 million
- Zacks · Oct 30, 8:05 AM EDTAurinia Pharmaceuticals (AUPH) Tops Q3 Earnings EstimatesAurinia (AUPH) delivered earnings and revenue surprises of +15.00% and -4.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 28, 9:00 AM EDTEarnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to DeclineIonis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 9:00 AM EDTEarnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to DeclineAurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 26, 8:45 AM EDTWhy Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Zacks · Oct 23, 8:50 AM EDTWhy Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- BNK Invest · Sep 24, 5:05 PM EDTNotable Thursday Option Activity: DHT, AUPH, ONTAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in DHT Holdings Inc (Symbol: DHT), where a total of 24,173 contracts have traded so far, representing approximately 2.4 million underlying shares. That amounts to about 61.
- Zacks · Aug 20, 12:23 PM EDTAurinia Settles Voclosporin Patent Litigation With Teva, Stock RisesAUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
- Zacks · Aug 6, 9:50 AM EDTAurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings EstimatesAurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 9:55 AM EDTNewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue EstimatesNewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 22, 7:40 AM EDTKaryopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · Jul 2, 12:00 PM EDTAurinia (AUPH) Upgraded to Strong Buy: Here's WhyAurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Aurinia Pharmaceuticals Inc from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.